BNP Paribas boosted its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 32.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,520 shares of the medical research company’s stock after purchasing an additional 14,541 shares during the period. BNP Paribas’ holdings in Amgen were worth $25,118,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp increased its holdings in Amgen by 38.2% during the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after purchasing an additional 11,656,755 shares during the last quarter. Bank of America Corp DE purchased a new position in shares of Amgen during the 2nd quarter valued at approximately $1,831,903,000. Wellington Management Group LLP boosted its stake in shares of Amgen by 1,102.7% during the 2nd quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock valued at $993,031,000 after buying an additional 2,514,254 shares during the last quarter. BlackRock Inc. grew its position in shares of Amgen by 4.8% during the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after buying an additional 2,261,544 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its position in shares of Amgen by 702.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company’s stock worth $647,126,000 after buying an additional 1,344,010 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.
Amgen Trading Down 0.8%
NASDAQ AMGN opened at $435.52 on Friday. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.20 and a current ratio of 1.48. Amgen Inc. has a one year low of $312.39 and a one year high of $483.99. The company has a 50-day simple moving average of $430.44 and a 200-day simple moving average of $383.81. The firm has a market capitalization of $235.58 billion, a PE ratio of 25.26, a price-to-earnings-growth ratio of 3.03 and a beta of 0.43.
Amgen Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. Amgen’s payout ratio is currently 58.47%.
Wall Street Analyst Weigh In
Several analysts recently issued reports on the stock. TD Cowen upped their price target on shares of Amgen from $452.00 to $531.00 and gave the company a “buy” rating in a report on Wednesday, November 4th. Leerink Partners raised their price objective on shares of Amgen from $395.00 to $464.00 and gave the stock a “market perform” rating in a report on Thursday, November 5th. Barclays boosted their target price on shares of Amgen from $400.00 to $430.00 and gave the stock an “equal weight” rating in a research report on Monday, November 16th. The Goldman Sachs Group upped their target price on shares of Amgen from $481.00 to $536.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. Finally, Argus lifted their price target on Amgen from $460.00 to $515.00 and gave the stock a “buy” rating in a research note on Thursday, November 12th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $428.62.
Get Our Latest Research Report on AMGN
Amgen Profile
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Read More
- Five stocks we like better than Amgen
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
